We report, to our knowledge, for the first time that the TNBC molecular subtype and IM signature frequently change after NST. Our results also suggest that EMT is promoted by NST. Our findings may lead to innovative adjuvant therapy strategies in TNBC cases with residual tumor after NST.

2 years ago

Journal

AR (Androgen receptor) • ITK (IL2 Inducible T Cell Kinase)

TNBCType-IM assay

over2years

Identification of AR driven tumors within TNBC using a novel gene signature (SABCS 2021)

Conclusion Identification of AR driven tumors within TNBC has both prognostic and predictive utility. Methods using limited number of AR regulated genes could be easily applied to larger BC cohorts to identify TNBC tumours driven by AR signalling and may respond well to anti-androgen therapies.

over 2 years ago

Gene Signature

ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • ITK (IL2 Inducible T Cell Kinase) • SOCS2 (Suppressor Of Cytokine Signaling 2) • TFF1 (Trefoil Factor 1)

TP53 mutation • PIK3CA mutation • AR positive • AR expression • ER overexpression • EMT gene signature

TNBCType-IM assay

almost4years

Oncocyte Announces Peer-Reviewed Publication of Data Demonstrating the Potential of its TNBCType Assay to Inform Triple Negative Breast Cancer Drug Development (GlobeNewswire)

"Peer reviewed research demonstrates the utility of the Oncocyte’s TNBCType-IM assay to identify the most suitable cell lines to help biopharma and academic researchers in their quest for treatments for TNBC, the deadliest form of breast cancer. . Published research demonstrates the test’s ability to work consistently both in vitro and in vivo in six cell lines used in drug development, suggesting promise in research applications."

almost 4 years ago

Preclinical

TNBCType-IM assay

TEST:TNBCType-IM assay

News

TEST:
TNBCType-IM assay